BILIARY TRACT CANCER (BTC)

This study tests a treatment for biliary tract cancer (a rare and aggressive cancer of the bile ducts or gallbladder) that cannot be removed by surgery. The approach combines hepatic arterial infusion chemotherapy (HAIC), which delivers high-dose chemo directly to the liver, with…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors, including stomach, pancreatic, and bile duct cancers. The main goals are to check the drug's safety, find the best dose, and see how the body process…

This study tests a new drug, Spevatamig, in people with advanced stomach, pancreatic, or bile duct cancers that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose of Spevatamig alone, then testing it combined with chemotherapy or …

This early-phase trial tests an experimental oral drug called ST-01156 in about 171 adults with advanced solid tumors, including Ewing sarcoma, liver cancer, and bile duct cancer. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dos…

This study tests a new treatment for people with advanced bile duct cancer whose standard first-line therapy has stopped working. The treatment combines a special form of the chemotherapy drug paclitaxel with immunotherapy. The goal is to see if this combination can shrink tumors…

This study tests a new drug called nanvuranlat in people with advanced biliary tract cancer (bile duct cancer) that has already been treated. About 480 adults will receive either nanvuranlat or standard treatments (chemotherapy or supportive care). The goal is to see if nanvuranl…

This study is collecting tissue and fluid samples from 160 people with suspected liver, bile duct, or pancreatic cancers. Researchers will analyze these samples to understand the cancers better and test new imaging and robotic tools for earlier, more accurate diagnosis. The goal …